“…4) Alter expression of nonhistone proteins including transcription factors and regulators, inflammation/immune response mediators, chaperones, DNA repair enzymes, and structural proteins [69,82,83,90]. These features of HDACIs are exploited as promising anticancer epi-drugs and several HDACIs have entered clinical trials in both hematologic and solid tumors [70,[72][73][74][75][81][82][83]90]. As such, HDACIs are investigated mainly as anticancer epi-drugs, even though HDAC enzymes also play a crucial role in other diseases such as cardiovascular disease [91], neurological disorders [92], immunological processes and viral infections [93], and other disorders [94].…”